Infrequent expression of p21 is related to altered p53 protein in pancreatic carcinoma

Clinical Cancer Research

Volumn 4, Issue 5, 1998, Pages 1147-1152

  Hu, Yu Xin ^a   Watanabe, Hiroyuki ^a   Ohtsubo, Koushiro ^a   Yamaguchi, Yasushi ^a   Ha, Aiguli ^a   Motoo, Yoshiharu ^a   Okai, Takashi ^a   Sawabu, Norio ^a  

^a KANAZAWA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; PROTEIN P21; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER STAGING; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PANCREAS CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; AGED; CARCINOMA; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM STAGING; PANCREATIC NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0031900457     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Hunter, T., and Pines, J. Cyclin and cancer II: cyclin and CDK inhibitors come of age. Cell, 79: 573-582, 1994.
2. EL-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parson, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., and Vogelstein, B. V. WAF1, a potential mediator of p53 tumor suppression. Cell, 75: 817-825, 1993.
3. Parker, S. B., Eicgele, G., Zhang, P., Rawls, A., Sands, A. T., Bradley, A., Olson, E. N., Harper, J. W., and Ellege, S. J. p53-independent expression of p21/Cip1 in muscle and other terminally differentiating cells. Science (Washington DC), 267: 1024-1027, 1995.
4. Michieli, P., Cheedid, M., Lin, D., Pierce, J. H., Mercer, W. E., and Givol, D. Introduction of WAF1/CIP1 by a p53-independent pathway. Cancer Res., 54: 3391-3395, 1994.
5. Gomyo, Y., Ikeda, M., Osaki, M., Tetebe, S., Tsujitani, S., Ikeguchi, M., Kaibara, N., and Ito, H. Expression of p21 (waf1/cip1/sdi1), but not p53 protein, is a factor in the survival of patients with advanced gastric carcinoma. Cancer (Phila.), 79: 2067-2072, 1997.
6. Ruggeri, B. A., Huang, L., Berger, D., Chang, H., Klein-Szanto, A. J. P., Goodrow, T., Wood, M., Obara, T., Heath, A. W., and Lynch, H. Molecular pathology of primary and metastatic ductal pancreatic lesions: analyses of mutations and expression of the p53, mdm-2, and p21/WAF-1 genes in sporadic and familial lesions. Cancer (Phila.), 79: 700-716, 1997.
7. Lundin, J., Nordling, S., von Boguslawaky, K., Roberts, P. J., and Haglund, C. Prognostic value of immunohistochemical expression of p53 in patients with pancreatic cancer. Oncology (Basel), 53: 104-111, 1996.
8. DiGiuseppe, J. A., Hruban, R. H., Goodman, S. N., Polak, M., van den Berg, F. M., Allison, D. C., Cameron, J. L., and Offerhaus, J. A. Overexpression of p53 protein in adenocarcinoma of the pancreas. Am. J. Clin. Pathol., 101: 684-688, 1994.
9. Boschman, C. R., Stryker, S., Reddy, J. K., and Rao, M. S. Expression of p53 protein in adenocarcinoma of the pancreas. Am. J. Pathol, 145: 1291-1295, 1993.
10. Zhang, S. Y., Ruggeri, B., Agarwal, P., Sorly, A. F., Obara, T., Yra, H., Namiki, M., and Klein-Szanto, J. P. Immunohistochemical analysis of p53 expression in human pancreatic carcinoma. Arch. Pathol. Lab. Med., 118; 150-154, 1994.
11. Shimizu, T., Miwa, W., Nakamori, S., Ishikawa, O., Konishi, Y., and Sekiya, T. Absence of a mutation of the p21/Waf1 gene in human lung and pancreatic cancers. Jpn. J. Cancer Res., 87: 275-278, 1996.
12. Shiohara, M., EL-Deiry, W. S., Wada, M., Nakamaki, T., Takeuchi, S., Yang, R., Chen, D-L., Vogelstein, B. V., and Koeffler, H. P. Absence of WAF1 mutations in a variety of human malignancies. Blood, 84: 3781-3784, 1994.
13. DiGiuseppe, J. A., Redston, M. S., Yeo, C. J., Kern, M. S., and Hruban, R. H. p53-independent expression of the cyclin-dependent kinase inhibitor p21 in pancreatic carcinoma. Am. J. Pathol., 147: 884-888, 1995.
14. WAF1/CIP-1 and p53 expression in pancreatic adenocarcinoma. Cancer (Phila.), 80: 372-381, 1997.
15. Cordon-Cardo, C., Zhang, Z-F., Dalbagni, G., Drobnjak, M., Charytonowicz, E., Hu, S-X., Xu, H-J., Reuter, V. E., and Benedict, W. F. Cooperative effects of p53 and Rb alterations in primary superficial bladder tumors. Cancer Res., 57: 1217-1221, 1997.
16. Klöppel, G. Pancreatic non-endocrine tumors. In: G. Klöppel (ed.), Pancreatic Pathology, pp. 79-113. Edinburgh, Scotland: Churchill Livingstone, 1984.
17. Hermreck, A. S., Thomas, C. Y., and Friesen, S. R. Importance of pathologic staging in the surgical management of adenocarcinoma of the exocrine pancreas. Am. J. Surg., 85: 653-657, 1974.
18. WAF1, and bcl-2 during colorectal tumorigenesis. In: E. Tahara (ed.), Recent Advances in Gastroenterological Carcinogenesis I, pp. 365-369. Bologna: Mondozzi, 1996.
19. Jian, H., Lin, J., Su, Z., Herlyn, M., Kerbel, R. S., Bernard, E., Weissman, B. E., Welch, D. R., and Fisher, P. B. The melanoma differentiation-associated gene mda-6, which encodes the cyclin-dependent kinase inhibitor p21, is differentially expressed during growth, differentiation, and progression in human melanoma cells. Oncogene, 10: 1855-1864, 1995.
20. WAF1/CIP1 in malignant melanoma: reduced expression in metastatic lesions. Am. J. Pathol., 149: 1813-1822, 1996.
21. WAF1 and p53 expression in breast carcinoma: an immunohistochemical study in 261 patients with long-term follow-up. Clin. Cancer Res., 2: 1591-1599, 1996.
22. Elbendary, A. A., Cirisano, F. D., Evans, A. C., Jr., Davis, P. L., Iglehart, J. D., Marks, J. R., and Berchuck, A. Relationship between p21 expression and mutation of the p53 tumor suppressor gene in normal and malignant ovarian epithelial cells. Clin. Cancer Res., 2: 1571-1575, 1996.
23. Missero, C., Calautti, E., Eckner, G., Chin, J., Tsai, L., Livingston, D. M., and Dotto, G. P. Involvement of the cell-cycle inhibitor Cip1/ Waf1 and the E1A-associated p300 protein in terminal differentiation. Proc. Natl. Acad. Sci. USA, 92: 5451-5455, 1995.
24. WAF1 in the maintenance of differentiating hepatoma cells. Gastroenterology, 112 (Suppl.): A1259, 1997.
25. Stincomb, N. Constraining the cell: regulation cell division and differentiation by gene therapy. Nat. Med., 1: 1004-1006, 1995.
26. Waf1/CiP1 protects against p53-mediated apoptosis of human melanoma cells. Oncogene, 14: 929-935, 1997.
27. Elbendary, A., Berchuck, A., Davis, P., Havrilesky, L., Bast, R. C., Inglehart, J. D., and Marks, J. R. Transforming growth factor β1 can induce CIP1/WAF1 expression independent of the p21 pathway in ovarian cancer cells. Cell Growth Differ., 5: 1301-1307, 1994.
28. Friess, H., Berberat, P., Schilling, M., Korc, M., and Buchler, M. W. Pancreatic cancer: the potential clinical relevance of alterations in growth factors and their receptors. J. Mol. Med., 74: 35-42, 1996.
29. waf1 expression and growth inhibition by transforming growth factor β involve the tumor suppressor gene DPC4 in human pancreatic adenocarcinoma cells. Cancer Res., 57: 3929-3934, 1997.
30. Cheng, X., Bargonetti, J., and Prives, C. p53, through p21 (WAF1/ CIP1), induces cyclin D1 synthesis. Cancer Res., 55: 4257-4263, 1995.
31. Gansauge, S., Gansauge, F., Ramadani, M., Stobbe, H., Rau, B., Harada, N., and Berger, H. G. Overexpression of cyclin D1 in human pancreatic carcinoma is associated with poor prognosis. Cancer Res., 57: 1634-1637, 1997.
32. Hu, Y-X., Watanabe, H., Ohtsubo, K., Yamaguchi, Y., Ha, A., Okai, T., and Sawabu, N. Frequent loss of p16 expression and its correlation with clinicopathological parameters in pancreatic carcinoma. Clin. Cancer Res., 3: 1473-1477, 1997.
33. Loda, M., Cukor, B., Tam, S. W., Lavin, P., Fiorentino, M., Draetta, G. F., Jessup, J. M., and Pagano, M. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat. Med., 3: 231-234, 1997.
34. Steeg, P. S., and Abrams, J. S. Cancer prognostics: past, present, and p27. Nat. Med., 3: 152-154, 1997.